NR1H4 and inflammatory bowel disease: Based on these results and the crucial roles of FXR in regulating NAFLD, repositioning of vidofludimus demonstrates that this potential IBD drug efficaciously ameliorated the NAFLD symptoms in ob/ob mice as expected, thus uncovering a novel disease indication and molecular basis for the drug development of vidofludimus.